Driving Innovation in Rare Disease | 2023 Nano-rare Patient Colloquium | Chris Viehbacher

Chris Viehbacher, Biogen President and CEO, discusses why the conventional drug development system isn't set up to help patients with rare diseases. Chris explains why n-Lorem is able to discover, develop, and provide personalized ASO medicines for nano-rare patients in particular, and what can be learned to help populations with a disease prevalence that falls outside of the nano-rare category.